# Translational Research and Interventional Oncology Research Program

> **NIH NIH P30** · VANDERBILT UNIVERSITY MEDICAL CENTER · 2024 · $124,453

## Abstract

PROJECT 006 – TRANSLATIONAL RESEARCH AND INTERVENTIONAL ONCOLOGY
RESEARCH PROGRAM
PROJECT SUMMARY/ABSTRACT
The Translational Research and Interventional Oncology Research Program (TR) is an integrated
transdisciplinary program that provides the opportunity for clinical investigators and laboratory scientists to
collaboratively address the rapidly changing landscape of cancer therapy. TR traverses multiple disciplines,
including precision oncology, clinical trials, cellular therapy, immuno-oncology and immune-toxicity, and TR
leaders aim to enhance the vital cross-fertilization across disparate fields that can improve oncologic practice.
Over the past five years, TR members have continued to lead large, multi-center clinical trials and have remained
scientifically productive with increased funding. The prior funding cycle has seen growth at both ends of that
spectrum in addition to strong productivity in terms of publications and federal grant funding. TR aspires to
promote and advance all facets of bi-directional translational oncology in solid and hematological malignancies
with the main purpose of optimizing patient outcomes that align with serving the needs of the Vanderbilt-Ingram
Cancer Center (VICC) catchment area and beyond. The specific aims are targeted to lead development and
implementation of practice-changing discoveries, including the oversight of clinical trials that are innovative,
investigator-initiated and/or accrue on national and international stages. The translational scientists in TR aim to
perform paradigm-shifting research that further informs the next generation of clinical trials. The advent of
immuno-oncology has identified a rapidly evolving unmet need to address the identification of patients at risk of
immune-toxicity and to standardize best practices for management of those toxicities. TR membership is well-
positioned to lead the field of immune-toxicity across the spectrum of checkpoint inhibitors, immune-cellular
therapy and allogeneic stem cell transplantations. There are 37 program members from seven departments and
two schools with $5.5M in total peer-reviewed funding and NCI making up 47% ($2.6M). Out of 826 publications,
16% are intra-programmatic and 24% are inter-programmatic. Members also have 546 collaborative publications
with investigators at other NCI-designated cancer centers.

## Key facts

- **NIH application ID:** 10900665
- **Project number:** 5P30CA068485-29
- **Recipient organization:** VANDERBILT UNIVERSITY MEDICAL CENTER
- **Principal Investigator:** Douglas B Johnson
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $124,453
- **Award type:** 5
- **Project period:** 1998-09-01 → 2025-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10900665

## Citation

> US National Institutes of Health, RePORTER application 10900665, Translational Research and Interventional Oncology Research Program (5P30CA068485-29). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10900665. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*